Opendata, web and dolomites

MESI-STRAT SIGNED

Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MESI-STRAT project word cloud

Explore the words cloud of the MESI-STRAT project. It provides you a very rough idea of what is the project "MESI-STRAT" about.

decision    patients    mechanisms    smes    computational    panel    therapy    detection    preclinical    modelers    successful    breast    driving    ineffective    translation    accounts    et    networks    integrate    explore    endocrine    relapse    highest    estrogen    data    health    serum    matched    interventions    pharmacogenomics    stratification    measured    monitoring    team    closely    recurrence    network    tumors    trial    diagnostics    predictive    bc    industrial    metabolic    poorly    treatments    patient    75    prevalence    accelerate    cohorts    longitudinal    omics    mechanism    disease    subgroups    ending    combination    metabolism    explored    mesi    validation    strat    reducing    quality    effectiveness    jointly    care    bioinformaticians    marker    follow    collection    positive    receptor    life    oncologists    cancer    biological    signaling    risk    medical    body    clinical    fluids    resistance    co    guide    resistant    er    panels    prior    therapies    avoiding    organization    metabolite    tissue    models    gt    surgical    experimentalists   

Project "MESI-STRAT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET INNSBRUCK 

Organization address
address: INNRAIN 52
city: INNSBRUCK
postcode: 6020
website: http://www.uibk.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.mesi-strat.eu
 Total cost 5˙949˙963 €
 EC max contribution 5˙949˙963 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) coordinator 1˙609˙163.00
2    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 870˙100.00
3    UNIVERSITETET I BERGEN NO (BERGEN) participant 679˙520.00
4    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 398˙706.00
5    UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET NO (TROMSO) participant 366˙925.00
6    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 353˙682.00
7    DE DUVE INSTITUTE BE (BRUXELLES) participant 289˙000.00
8    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 258˙687.00
9    STIFTUNG PATIENTS TUMORBANK OF HOPE- DIE PATIENTENEIGENE TUMORGEWEBEBANK DER HOFFNUNG (PATH) DE (AUGSBURG) participant 250˙550.00
10    HITS GGMBH DE (HEIDELBERG) participant 224˙687.00
11    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 223˙524.00
12    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 190˙956.00
13    NEUROIMMUN GMBH DE (KARLSRUHE) participant 131˙750.00
14    SYSBIOSIM BV NL (LEIDEN) participant 102˙711.00
15    UNIVERSITY OF DURHAM UK (DURHAM) participant 0.00

Map

 Project objective

Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-based stratification of patients into subgroups with different ET resistance mechanisms. We will establish predictive models for (1) patient stratification prior and during ET; (2) recurrence risk assessment when ending ET; (3) marker panel development to guide targeted therapies for ET-resistant patients; (4) novel ET resistance mechanism-based therapy design.

The unique collection of matched BC tissue, serum, and >10 years follow-up from the patient organization PATH is essential for the longitudinal analysis of ET resistance and relapse. Our team of oncologists, modelers, bioinformaticians and experimentalists will develop new computational models in combination with network analyses and pharmacogenomics, to integrate multi-omics data and explore metabolic and signaling (MESI) networks driving ET resistance. Metabolite marker panels measured in biological fluids will enable patient stratification, resistance monitoring and clinical decision-making. This is a new concept as BC metabolism is poorly explored for diagnostics and therapy. Upon successful validation in preclinical models, the predictive marker panels and related treatments will be jointly investigated by our clinical and industrial partners in clinical studies. Our 3 SMEs will closely co-develop the research, and directly exploit the MESI-STRAT results. BC accounts for the highest cancer-related health-care costs in the EU. Our stratification concepts will increase cost effectiveness and the patients’ quality of life by (1) avoiding ineffective therapies, (2) marker detection in body fluids without surgical interventions, and (3) reducing clinical trial cohorts by improved stratification. This will accelerate the translation of MESI-STRAT results into medical use.

 Deliverables

List of deliverables.
MESI-STRAT website with continuous updates Websites, patent fillings, videos etc. 2020-04-07 22:43:30

Take a look to the deliverables list in detail:  detailed list of MESI-STRAT deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Mayra Diosa-Toro, Berit Troost, Denise van de Pol, Alexander Martin Heberle, Silvio Urcuqui-Inchima, Kathrin Thedieck, Jolanda M. Smit
Tomatidine, a novel antiviral compound towards dengue virus
published pages: 90-99, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2018.11.011
Antiviral Research 161 2020-04-07
2018 Mahdi Shafiee Kamalabad, Alexander Martin Heberle, Kathrin Thedieck, Marco Grzegorczyk
Partially non-homogeneous dynamic Bayesian networks based on Bayesian regression models with partitioned design matrices
published pages: 2108-2117, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/bty917
Bioinformatics 35/12 2020-04-07
2019 Michael Platten, Ellen A. A. Nollen, Ute F. Röhrig, Francesca Fallarino, Christiane A. Opitz
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
published pages: 379-401, ISSN: 1474-1776, DOI: 10.1038/s41573-019-0016-5
Nature Reviews Drug Discovery 18/5 2020-04-07
2019 Alexander Martin Heberle, Patricia Razquin Navas, Miriam Langelaar-Makkinje, Katharina Kasack, Ahmed Sadik, Erik Faessler, Udo Hahn, Philip Marx-Stoelting, Christiane A Opitz, Christine Sers, Ines Heiland, Sascha Schäuble, Kathrin Thedieck
The PI3K and MAPK/p38 pathways control stress granule assembly in a hierarchical manner
published pages: e201800257, ISSN: 2575-1077, DOI: 10.26508/lsa.201800257
Life Science Alliance 2/2 2020-04-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESI-STRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MESI-STRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More  

CANDY (2020)

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More